DECISION-Project

📢 Excited to share our latest publication from DECISION members, where we developed a fast and reproducible animal model of advanced MASH-cirrhosis in rats. By using a combination of CCl4, a high-fat Western diet (WD), and phenobarbital (PB), we've been able to mimic the key histological and pathophysiological features of decompensated MASH-cirrhosis seen in humans. 🔬 In just a shorter timeframe compared to existing models, this approach accurately reflects the advanced stage of the disease, making it an excellent tool for the development of new pharmacological treatments for MASH-cirrhosis. For more details, read the full paper here: 🔓 https://lnkd.in/dGs6TQS6 Special thanks to MDPI OpenAccess! Congrats to first authors Nico Kraus and Frank Erhard Uschner, as well as all contributing authors: Magnus Möslein, Robert Schierwagen, Wenyi Gu, Maximilian Brol, Elke Fürst, Inga Grünewald, Sophie Lotersztajn, Pierre-Emmanuel Rautou, Marta Duran Güell, PhD, Roger Flores Costa, Joan Claria, Jonel Trebicka, and Sabine Klein MedB LAB EASL | The Home of Hepatology European Foundation for the Study of Chronic Liver Failure (EF CLIF) #LiverResearch #Cirrhosis #MASH #Hepatology #DrugDevelopment #LiverDisease #AnimalModels #LiverHealth

As this year comes to an end, we take a moment to reflect on the progress made by the DECISION consortium in 2024. Thanks to the dedication of our teams and collaborators, we’ve reached important milestones that advance our mission to improve the understanding and treatment of liver diseases. Some of the highlights of this year include: 📄 𝗞𝗲𝘆 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 Two important subprojects of DECISION were published this year: 🔵 Decompensated MASH-cirrhosis model by acute and toxic effects of phenobarbital: This study, a significant contribution of DECISION's Work Package 4, introduced a fast and reproducible rat model mimicking advanced MASH-cirrhosis, a crucial tool for testing new therapeutic approaches. By combining carbon tetrachloride (CCl4), a high-fat Western diet, and phenobarbital, the model captures the key features of decompensated MASH-cirrhosis seen in humans, paving the way for more effective drug development. Read the paper here: https://lnkd.in/dGs6TQS6 🔵 A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis: A major output of our Work Package 3, the ClustALL pipeline was developed to address patient heterogeneity in acutely decompensated cirrhosis. This innovative clustering method identified unique patient subgroups with prognostic value and could improve clinical trial design and personalized patient management. Read the paper here: https://lnkd.in/dKZexXhE 💡 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗖𝗢𝗠𝗕𝗔𝗧 𝗧𝗿𝗶𝗮𝗹 This year also marked the inclusion of the first patient in the COMBAT trial. This multicenter Phase II study aims to evaluate the safety, efficacy, and cost-effectiveness of a combinatorial therapy using human albumin and enoxaparin alongside standard medical care. To all our collaborators, partners, and supporters—thank you for being an integral part of DECISION’s journey. Wishing you a joyous holiday season and a successful year ahead! #DECISIONproject #LiverResearch #COMBATtrial #Hepatology #cirrhosis

Researchers in the DECISION-Project developed a new animal model that allows for the study of metabolic dysfunction-associated steatohepatitis #MASH progression to #cirrhosis in just 6-8 weeks, offering a faster way to test potential treatments. Read the full story from our partners at MedB LAB Universitätsklinikum Münster and Universitätsmedizin Frankfurt: https://lnkd.in/dA6rJtmE Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Fundació Clínic per a la Recerca Biomèdica CRI - Centre de Recherche sur l'Inflammation

🚨 New video out now! Join Sara Palomino Echeverría, first author of DECISION's ClustALL paper, as she explains how this innovative patient stratification tool helps improve clinical management of acutely decompensated cirrhosis. By utilizing unsupervised clustering, ClustALL uncovers patterns in patient data, offering valuable insights and a user-friendly calculator for clinicians. Watch now! 🎥👇  https://lnkd.in/dpw7duyp   🔗 Read the full publication: https://lnkd.in/dKZexXhE  🖥️ Try the online calculator: https://lnkd.in/dmZ6uXjt   We are thankful to Lidia Garcia-Campmany from European Foundation for the Study of Chronic Liver Failure (EF CLIF) for the excellent work on the video production! 🙏   The DECISION project is dedicated to advancing the understanding of cirrhosis, aiming to reduce short-term mortality and develop personalized therapies for patients. European Liver Patients' Association - ELPA EASL | The Home of Hepatology #LiverDisease #Stratification #ACLF #Cirrhosis

The 6th DECISION-Project General Assembly highlighted the development of novel treatments and prognostic tools for #chronicliverdisease, with a focus on multi-omics data integration, relevant preclinical models, and the design of a clinical trial to test a new combinatorial therapy in patients with acutely decompensated cirrhosis. Under the coordination of Pierre-Emmanuel Rautou, the project is making steady progress towards its goals. Read more: https://lnkd.in/dRpF6rX7 Huge thanks to all partners in the Consortium for your continued dedication! Fundació Clínic per a la Recerca Biomèdica - Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Uniklinik RWTH Aachen Navarrabiomed, biomedical research centre YouHealth AB University of Bologna (Alma Mater Studiorum – Università di Bologna) UCL Università degli Studi di Padova (UNIPD) / University of Padua Università degli Studi di Torino Universitat de Barcelona EASL | The Home of Hepatology European Liver Patients' Association - ELPA concentris research management GmbH #Horizon2020

🔵 October is #LiverCancerAwarenessMonth, and the fight against #liverdisease is more critical than ever. We at ELPA are proud to be part of the DECISION-Project EU project European Health and Digital Executive Agency (HaDEA) , which is dedicated to reducing the high mortality rates of patients suffering from decompensated #cirrhosis and related #liverconditions. 🧬 #DECISION4LIVER aims to uncover the underlying mechanisms of decompensated cirrhosis, leading to acute-on-chronic liver failure (#ACLF). By studying large, well-characterized patient cohorts, we’re working toward personalized therapies that will transform outcomes for those affected. 🛠️ Key objectives: 1️⃣ Develop a prognostic test to identify patients at risk of poor outcomes following standard treatments. 2️⃣ Create a response test to predict the success of novel combinatorial therapies, offering an alternative to invasive solutions like liver transplants. Together, it’s #OURDECISION to reduce mortality and improve lives! 📅 This October 16-18, we're gathering at the 6th General Assembly Meeting in Bologna, Italy, to continue advancing this mission. #LiverHealth #Hepatology #LiverDisease #Cirrhosis #MedicalResearch #ACLF #PersonalizedMedicine #LiverTransplant #DECISION4Liver #HealthInnovation MICROB-PREDICT A-TANGO Nina Donner (PhD) Jonel Trebicka Aleksander Krag EASL the home of Hepatology UEG - United European Gastroenterology International Liver Cancer Association (ILCA) EU Health and Food Safety WHO Regional Office for Europe ESMO - European Society for Medical Oncology European Commission European Medicines Agency Marko Korenjak Veronika Všetíčková Beatrice Credi MSc Milan Mishkovikj, M.A. Manuel Romero Gomez European Patients' Forum Anastassiya Semeiskaya

Our #GeneralAssembly meeting is coming to an end. We had a wonderful time in #Bologna, discussed our latest research results and leave here with our heads full of new ideas for projects and collaboration! 💡 Stay tuned! Save travels home everyone! European Foundation for the Study of Chronic Liver Failure (EF CLIF) Pierre-Emmanuel Rautou Richard Moreau Cristina Sanchez Ferran Aguilar Parera Anna Bosch Comas Fundació Clínic per a la Recerca Biomèdica Joan Claria Uniklinik RWTH Aachen Tony Bruns Priv.-Doz. Dr. med. Theresa Wirtz Reißing Johanna Navarrabiomed, biomedical research centre David Gomez-Cabrero Núria Planell Estefanía Huergo Iglesias YouHealth AB Narsis Aftab Kiani University of Bologna (Alma Mater Studiorum – Università di Bologna) CARACENI Paolo Greta Tedesco Giacomo Zaccherini Giulia Iannone, Enrico Pompili, Maurizio Baldassarre UCL Raj Mookerjee Olivia Greenham Uni Padua Sara Montagnese Uni Torino Carlo Alessandria Daniela Campion Itziar de Lecuona, PhD EASL | The Home of Hepatology European Liver Patients' Association - ELPA Beatrice Credi Marko Korenjak concentris research management GmbH Sonja Leissner Tamara Breitinger MedB LAB Jonel Trebicka Sabine Klein Frank Erhard Uschner #EUfunded #Horizon2020

DECISION's 6th General Assembly meeting started with a deep-dive into the particularities of inflammation in acute decompensation of cirrhosis and acute-on-chronic liver failure (#ACLF). A keynote lecture provided by Richard Moreau, director of European Foundation for the Study of Chronic Liver Failure (EF CLIF). 🥁 𝗦𝘁𝗮𝗿𝘁𝗶𝗻𝗴 𝘀𝗶𝗴𝗻𝗮𝗹! Coordinator Pierre-Emmanuel Rautou then officially kicked off our 6th General Assembly meeting, and directly continued with a series of #paperpresentations: 📝 #epigenetics signatures (from whole-blood and single-cell), presented by Estefanía Huergo Iglesias, of Navarrabiomed, biomedical research centre.  📝 💉 Whole-blood #transcriptomics in relation with outcome of decompensation of #cirrhosis, by Richard Moreau. 📝 Serum #microRNA profiles associated with decompensation of #cirrhosis. Presented by Reißing Johannaof Uniklinik RWTH Aachen. 📝 Plasma inflammatory protein (#cytokines) and lipid mediators (eicosanoids) characterization - common paper with #metabolomics, by Cristina López Vicario of Fundació Clínic per a la Recerca Biomèdica 📝 Plasma #extracellularvesicle signatures as markers of tissue damage and cell injury, presented by Pierre-Emmanuel on behalf of Shantha Valainathan of Greater Paris University Hospitals - AP-HP Next up were: Work package presentations! 🧪  WP4: Selection and validation of combinatorial therapies using #preclinical rat models. Presented by Frank Erhard Uschner from partner Universitätsklinikum Münster’s MedB LAB WP3: #Patientstratification, development of prognostic and response tests and of new combinatorial therapies for decompensated cirrhosis using #systemsapproach|es by David Gomez-Cabrero of Navarrabiomed, biomedical research centre. Day 1 of DECISION’s GA was wrapping up with a #masterclass on #clinical #bioinformatics by David Gomez-Cabrero, Núria Planell, and Cristina Sanchez. 🚀 DECISION’s General Assembly Meeting Day 2 started off with an update of Work Package 7, which is is all about dissemination, #ScienceCommunication, training for young researchers and guideline development. Tamara Breitinger from concentris research management GmbH presented an overview of the highlights in DECISION's project communication. Next up, CARACENI Paolo, our host here in Bologna, presented an update on WP5, our #ClinicalStudy #COMBATtrial and our observational study PROSPECT. Then followed what we love about our General Assemblies: We get to receive quality #feedback from our Scientific and Ethical Advisory Board Members Dr. Hermann Mucke, and Prof. Dominique Valla. Second to lastly, we were honored by a presentation of Dr. Dean Hum, Chief Scientific Officer at GENFIT. Last, but not least, Pierre-Emmanuel Rautou closed the meeting with his conclusions and with this wrapped up our sixth General Assembly Meeting! #EUfunded #Horizon2020 #cirrhosis #hepatology #genomics #liverresearch

✨We’re excited for our 6️⃣th General Assembly Meeting in #Bologna 🇮🇹! Together, DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level! For more info, visit 🌐 https://lnkd.in/d28efzVh European Foundation for the Study of Chronic Liver Failure (EF CLIF) Pierre-Emmanuel Rautou Richard Moreau Cristina Sanchez Ferran Aguilar Parera Anna Bosch Comas Fundació Clínic per a la Recerca Biomèdica Joan Claria Priv.-Doz. Dr. med. Theresa Wirtz Reißing Johanna Navarrabiomed, biomedical research centre David Gomez-Cabrero Núria Planell Estefanía Huergo Iglesias YouHealth AB Narsis Aftab Kiani CARACENI Paolo Greta Tedesco Raj Mookerjee Sara Montagnese Carlo Alessandria Daniela Campion Itziar de Lecuona, PhD EASL | The Home of Hepatology European Liver Patients' Association - ELPA Tamara Breitinger concentris research management GmbH Sonja Leissner MedB LAB Jonel Trebicka Sabine Klein Frank Erhard Uschner

Don't miss Coordinator of the DECISION-Project Pierre-Emmanuel Rautou from CRI - Centre de Recherche sur l'Inflammation on 2 October 2024 11:30–11:55 CET at the XV International Meeting on Therapy in #LiverDiseases (in-person and online), to learn about treatment of #portalvein thrombosis . Register now: https://lnkd.in/dNpxg7Gh